Hosted on MSN6d
Converting IV-drip Medications into Shots
Biopharma company Halozyme Therapeutics is on a mission to replace IV-drug delivery. It develops subcutaneous devices to make it easier and quicker to inject high-volume drugs into patients. Halozyme ...
bovnews6d
Halozyme Therapeutics, Inc. (HALO) Stock’s 0.14% Increase This Year: What’s the Story?
Halozyme Therapeutics, Inc. (HALO) stock saw a modest uptick, ending the day at $54.51 which represents a slight increase of $0.68 or 1.26% from the prior close of $53.83. The stock opened at $54.39 ...